All In Biotech

Drug Trial Radar · NCT05072522

A Study of SKLB1028 in Patients With Advanced Solid Tumor

An Open-label, Multicenter, Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of SKLB1028 in Patients With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Oct 11, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

98

Planned (sponsor's estimate)

Start

Oct 2021

Primary completion

Oct 2023

Study completion Oct 2023

Sponsor

Sponsor type
Industry
First posted
Oct 11, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of SKLB1028 in patients with advanced solid tumors.

Conditions

  • Advanced Solid Tumors

Interventions

  • SKLB1028Drug

    SKLB1028 capsules, oral, once daily in continuous 28-day cycles

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose limiting toxicity (DLT)Time frame: At the end of Cycle 1 (each cycle is 28 days)
  2. Maximum tolerated dose (MTD)Time frame: At the end of Cycle 1 (each cycle is 28 days)
  3. Treatment Emergent Adverse Event (TEAE)Time frame: From the initiation of the first dose to 28 days after the last dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Henan Cancer Hospital

    Zhengzhou, Henan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.